JP7693691B2 - Ｐ２ｘ３アンタゴニストの製造 - Google Patents
Ｐ２ｘ３アンタゴニストの製造 Download PDFInfo
- Publication number
- JP7693691B2 JP7693691B2 JP2022548876A JP2022548876A JP7693691B2 JP 7693691 B2 JP7693691 B2 JP 7693691B2 JP 2022548876 A JP2022548876 A JP 2022548876A JP 2022548876 A JP2022548876 A JP 2022548876A JP 7693691 B2 JP7693691 B2 JP 7693691B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- mixture
- difluoro
- morpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977004P | 2020-02-14 | 2020-02-14 | |
| US62/977,004 | 2020-02-14 | ||
| US202163144902P | 2021-02-02 | 2021-02-02 | |
| US63/144,902 | 2021-02-02 | ||
| PCT/IB2021/000130 WO2021161109A1 (en) | 2020-02-14 | 2021-02-12 | Preparation of a p2x3 antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023513738A JP2023513738A (ja) | 2023-04-03 |
| JP2023513738A5 JP2023513738A5 (https=) | 2024-02-20 |
| JP7693691B2 true JP7693691B2 (ja) | 2025-06-17 |
Family
ID=77292130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548876A Active JP7693691B2 (ja) | 2020-02-14 | 2021-02-12 | Ｐ２ｘ３アンタゴニストの製造 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12503470B2 (https=) |
| EP (1) | EP4103572A4 (https=) |
| JP (1) | JP7693691B2 (https=) |
| KR (1) | KR20220140804A (https=) |
| CN (1) | CN115427419B (https=) |
| AU (1) | AU2021219992A1 (https=) |
| BR (1) | BR112022015818A2 (https=) |
| CA (1) | CA3184277A1 (https=) |
| IL (1) | IL295394A (https=) |
| MX (1) | MX2022009765A (https=) |
| WO (1) | WO2021161109A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7578602B2 (ja) | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| WO2022156783A1 (zh) * | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN114805237B (zh) * | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| WO2022161462A1 (zh) * | 2021-01-29 | 2022-08-04 | 上海海雁医药科技有限公司 | 吗啉衍生物及其药物组合物和用途 |
| WO2023021328A1 (en) * | 2021-08-17 | 2023-02-23 | Bellus Health Cough Inc. | Preparation of a p2x3 antagonist |
| EP4577528A1 (en) * | 2022-08-25 | 2025-07-02 | 14245563 Canada Inc. | Preparation of a p2x3 antagonist |
| WO2025125445A1 (en) | 2023-12-12 | 2025-06-19 | Glaxosmithkline Intellectual Property (No.3) Limited | Process of manufacture of p2x3 antagonists including camlipixant |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2026022326A1 (en) | 2024-07-25 | 2026-01-29 | Glaxosmithkline Intellectual Property (No.3) Limited | P2x3 antagonist formulation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506935A (ja) | 2013-01-31 | 2016-03-07 | ネオメド・インスティチュート | イミダゾピリジン化合物及びその使用 |
| WO2020135771A1 (zh) | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010229142A1 (en) * | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| CN102358739B (zh) * | 2011-04-29 | 2013-02-20 | 中国科学院广州生物医药与健康研究院 | 咪唑[1,2-a]吡啶和咪唑醛类化合物的合成方法 |
| US10111883B1 (en) | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| EP4103564A4 (en) * | 2020-02-14 | 2024-05-01 | GlaxoSmithKline Intellectual Property (No.3) Limited | P2X3 MODULATORS |
| WO2021244634A1 (zh) | 2020-06-05 | 2021-12-09 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| EP4169921A4 (en) | 2020-06-29 | 2024-06-19 | Wuhan LL Science and Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| WO2022156783A1 (zh) | 2021-01-22 | 2022-07-28 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| CN114805237B (zh) | 2021-01-22 | 2026-04-21 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
-
2021
- 2021-02-12 CN CN202180028877.XA patent/CN115427419B/zh active Active
- 2021-02-12 JP JP2022548876A patent/JP7693691B2/ja active Active
- 2021-02-12 EP EP21754068.1A patent/EP4103572A4/en active Pending
- 2021-02-12 WO PCT/IB2021/000130 patent/WO2021161109A1/en not_active Ceased
- 2021-02-12 US US17/929,027 patent/US12503470B2/en active Active
- 2021-02-12 AU AU2021219992A patent/AU2021219992A1/en not_active Abandoned
- 2021-02-12 IL IL295394A patent/IL295394A/en unknown
- 2021-02-12 BR BR112022015818A patent/BR112022015818A2/pt unknown
- 2021-02-12 CA CA3184277A patent/CA3184277A1/en active Pending
- 2021-02-12 MX MX2022009765A patent/MX2022009765A/es unknown
- 2021-02-12 KR KR1020227031508A patent/KR20220140804A/ko active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016506935A (ja) | 2013-01-31 | 2016-03-07 | ネオメド・インスティチュート | イミダゾピリジン化合物及びその使用 |
| WO2020135771A1 (zh) | 2018-12-29 | 2020-07-02 | 武汉朗来科技发展有限公司 | 杂环类化合物、中间体、其制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL295394A (en) | 2022-10-01 |
| BR112022015818A2 (pt) | 2022-10-25 |
| MX2022009765A (es) | 2022-09-09 |
| US20230101612A1 (en) | 2023-03-30 |
| JP2023513738A (ja) | 2023-04-03 |
| KR20220140804A (ko) | 2022-10-18 |
| CA3184277A1 (en) | 2021-08-19 |
| CN115427419A (zh) | 2022-12-02 |
| EP4103572A4 (en) | 2024-03-06 |
| WO2021161109A1 (en) | 2021-08-19 |
| CN115427419B (zh) | 2026-04-21 |
| EP4103572A1 (en) | 2022-12-21 |
| US12503470B2 (en) | 2025-12-23 |
| AU2021219992A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7693691B2 (ja) | Ｐ２ｘ３アンタゴニストの製造 | |
| JP4249012B2 (ja) | 新規な２ｈ−ピリダジン−３−オン誘導体、該誘導体を含有する医薬組成物及びこの有効成分の製法 | |
| TW200522933A (en) | Muscarinic acetylcholine receptor antagonists | |
| WO2023021328A1 (en) | Preparation of a p2x3 antagonist | |
| TW202334103A (zh) | 用於治療痛風或高尿酸血症之化合物之製備 | |
| EP3022201A1 (en) | Autotaxin inhibitors | |
| TWI555738B (zh) | 苯并噻唑酮化合物 | |
| JP4225894B2 (ja) | 縮合環式基を有する環状ジアミン化合物 | |
| JP2026504060A (ja) | Ｓ１ｐ受容体モジュレーターの調製 | |
| TW201000480A (en) | Imidazo pyridine derivatives | |
| HK40084747A (en) | Preparation of a p2x3 antagonist | |
| CN119790042A (zh) | P2x3拮抗剂的制备 | |
| ES2715348T3 (es) | Compuestos que contienen anillos de nitrógeno fusionados para su uso como antagonistas de CRTH2 | |
| HK40113882A (zh) | 用於治疗痛风或高尿酸血症的化合物的制备 | |
| EP3630100A1 (en) | Fused bicyclic compounds | |
| JPH08512308A (ja) | Ｄ１アンタゴニスト／ｄ２アンタゴニスト及び５ｈｔ２−セロトニンアンタゴニストとしてのピペリジニル置換メタノアントラセン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240209 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240610 Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20240610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250605 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7693691 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |